Connect with us

News

Zoomlion Wows at bauma China 2020 Exhibition with Launch of Next-Gen Intelligent Construction Machinery Securing Over $US3 Billion in Orders

Published

on

Zoomlion Wows at bauma China 2020 Exhibition with Launch of Next-Gen Intelligent Construction Machinery Securing Over $US3 Billion in Orders

Zoomlion Heavy Industry Science & Technology Co., Ltd. (Zoomlion) has presented its largest outdoor exhibition at bauma China 2020 in Shanghai and launched multiple high-end intelligent products during the three-day international trade fair.

Zoomlion is exhibiting over 50 sets of construction equipment products from nine product lines at bauma China 2020. Through new product releases and online livestreaming events to interact with global customers, Zoomlion has signed orders totaling CNY20 billion ($US3.04 billion) at bauma China as of 26 November.

“The exhibition highlights Zoomlion’s high-end 4.0 generation products and innovative achievements that represent a qualitative leap of intelligence,” said Mr. Guo Xuehong, Vice President of Zoomlion.

Taking the lead in the industry with high-end, innovative intelligent products

Zoomlion’s exhibition at bauma China 2020 offered a glimpse into the future of construction machinery with a demonstration of intelligent hoisting minus the operation cab but with a 5G remote control experience center giving the “intelligence” part of the equipment the ability to touch, sense and see.

The ZTC-250NEV is the world’s first electric truck crane which has integrated machine vision, artificial intelligence and 5G communication, it’s a cab-less crane but with “eyes and a brain” to complete smart hoisting tasks with the push of a button.

The ZCC18000 crawler crane has the highest tonnage at the trade fair, boasting great hoisting capacity that makes it a perfect model for wind power hoisting on land and at sea. It’s equipped with Zoomlion’s self-developed no-landing overloading counterweight technology that reduces the area of operation by 60% and delivers industry-leading lifting performance.

Zoomlion also released the ZT68J, a self-propelled straight-arm aerial work platform that sets a world record of 67.5 meters in height, while guaranteeing better performance in off-road operation and intelligent control.

The company’s dry-mix mortar equipment has adopted the patented ultra-high-precision automatic powder metering system Powerdos. The intelligent functions such as hollow boom technology, carbon fiber concrete pipe and man-machine voice interaction and a tower crane ETI smart control system were widely acclaimed by visitors to the fair and global livestreaming audiences alike.

As the global market recovers from the impacts of COVID-19, Zoomlion is persisting with innovative research and development and looks forward to creating and sharing with all partners. The exhibitor hosted a 24-hour livestream in Chinese and English allowing global customers to participate in bauma China 2020.

“Zoomlion has never changed its vision to share the industry’s achievements and co-build the industry’s ecosphere. We are expecting to shape an intelligent and ultimate future in the principles of extensive consultation, joint contribution and shared benefits,” said Mr. Guo.

About Zoomlion

Founded in 1992, Zoomlion Heavy Industry Science & Technology Co., Ltd. (01157.HK) is a high-end equipment manufacturing enterprise that integrates engineering machinery, agricultural machinery, and financial services. The company now sells more than 600 cutting-edge products from 56 product lines covering ten significant categories.

Health

4baseCare and ACTREC-Tata Memorial Centre join hands for development of AI based clinical interpretation platform

Published

on

4baseCare and ACTREC-Tata Memorial Centre join hands for development of AI based clinical interpretation platform

This AI driven tool will support oncologist in clinical decision making and to offer precision medicine to cancer patients.

4baseCare, an Illumina Accelerator backed Precision Oncology start-up and ACTREC (Advanced Centre for Treatment, Research and Education in Cancer) – Tata Memorial Centre have signed a collaboration agreement for an AI driven clinical interpretation platform, ClinOme. The collaboration aims at making an indigenous platform to generate data insights and simplified reports to guide oncologists with personalised treatment options for treating cancer patients.

ClinOme is a Graphical User Interface (GUI) based automated tool developed by senior scientists & clinicians from ACTREC & Tata Memorial Hospital by Dr. Amit Dutt, Dr. Pratik Chandrani and Dr. Kumar Prabhash for analysis of raw NGS data followed by comprehensive clinical report generation. It automates quality check, primary, secondary and tertiary analysis of raw NGS data followed by report generation that can be easily comprehended by the clinicians. It provides easy to interpret categorization of genomic alterations along with approved and experimental therapeutic options for each responsive and resistant genotype-drug combination.

Dr. Amit Dutt, Principal Investigator, Scientist, ACTREC -Tata Memorial Hospital, says, “Patient-to-patient variation in treatment response as observed routinely in clinics, suggests that personal targeting of cancer, based on tumour molecular profiles, is necessary. The ClinOme tool and our collaborative work with 4baseCare is likely to benefit large numbers of oncologists in a democratic manner who could take advantage of artificial intelligence-based automation of NGS data analysis to decide an appropriate therapeutic regimen tailored to the patient’s genomic alterations. This is a huge step forward to scale the digital curation towards precision medicine.”

4baseCare having an exclusive worldwide license to ClinOme, plans to invest significant time and resources to further develop and enhance the functionality and precision of ClinOme.

“We are very happy to associate with ACTREC_TMC to introduce ClinOme. The objective of this collaboration is to improve the treatment process and enhancing patients’ quality of life. This partnership is a first step towards developing an advanced ecosystem where researchers & clinicians practice together leading to the development of a solution which has immediate translational benefits for the patients,” says Kshitij Rishi, COO 4baseCare.

“We at 4baseCare are excited to build upon the remarkable research-based product developed by ACTREC-TMC as a robust AI driven platform to support the oncologist(s) in their clinical decision making,” says Hitesh Goswami CEO, 4baseCare.

This collaboration will set a great precedence for Industry-academia collaboration towards translational research. It will also be a huge step towards personalisation of treatment for Indian cancer patients and aligns with the vision of both ACTREC-TMC and 4baseCare of improving quality of life and treatment of cancer patients of the country.

“Genomic testing has become important in the management of cancer. NGS is emerging as a comprehensive solution for genomic testing. It a complex process where the bioinformatics pipeline is a very important component. ClinOme provides a very useful indigenous solution in this area,” says Dr. Kumar Prabhash, Professor and Medical Oncologist, Tata Memorial Hospital.

The output of ClinOme analysis consists of a report with detailed patient centric genotype to help design informed therapeutic option. The output report also consists of links to the specific ongoing clinical trials, gene wise coverage statistics and allelic frequency of the genomic variants.

“While genomics data analysis is a challenge, evidence based therapeutic inference is altogether another challenge. ClinOme addresses both of the challenges using a combination of genomics best practices and artificial-intelligence powered evidence based therapeutic inference,” says Dr. Pratik Chanarani is Scientific Officer, ACTREC-Tata Memorial Hospital.

About 4baseCare

4baseCare is the 1st company from Asia Pacific to be backed by Global genomics leader Illumina through their Illumina Accelerator Program. It develops affordable and accessible precision oncology solutions using Genomics and Digital Health technology to personalise patient care in Oncology.

4baseCare has developed custom gene panels that allow oncologists to characterise and understand the molecular signature of individuals’ cancer patient’s tumour tissue. Based on 4baseCare’s reports, the oncologists can then tailor and personalise treatment for their patients.  4baseCare has undertaken one of the largest cohort study of cancer patients to develop first of its kind Indian population specific gene panel in collaboration with clinical partners from AIIMS, ACTREC-TMC, St John’s Research Institute (SJRI) and Fortis (Bangalore).

Please visit: www.4basecare.com.

About ACTREC- Tata Memorial Centre

The origins of the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) are rooted in the Indian Cancer Research Centre (ICRC) which was renamed the Cancer Research Institute (CRI) and amalgamated with the Tata Memorial Hospital (TMH), creating the first comprehensive cancer centre in India – the Tata Memorial Centre (TMC), an autonomous grant-in-aid institution of the Department of Atomic Energy (DAE), Government of India.

ACTREC started with a basic research division focus on providing novel therapeutic strategies for the treatment of cancer. The Tata Memorial Centre’s mission is to provide comprehensive cancer care to one and all, through its motto of excellence in services, education and research.

Continue Reading

News

Gardner Capital Breaks Ground on Brand-New Senior Community in Hurst

Published

on

Gardner Capital Breaks Ground on Brand-New Senior Community in Hurst

Supporting the growing need for senior housing in the densely populated Dallas-Ft. Worth metro, Gardner Capital has broken ground on Gala at Central Park in Hurst. A family-owned private equity firm specializing in multifamily housing and renewable energy development and investment, Gardner Capital aims to complete construction in early 2022.

Treymore Construction will serve as general contractor for the project, to be located at 309 W. Pipeline Rd. in Hurst. Hurst Public Facility Corporation is the development partner for Gala at Central Park, while NDC Corporate and Redstone are the financial partners for the transaction.

“A couple years ago the City of Hurst realized that we need to address a growing problem in our city, said Henry Wilson,” Mayor of City of Hurst.  “That problem was sufficient workforce and senior housing.  We were so fortunate to develop a community revitalization relationship with Gardner Capital. We now have new communities open or under development to further address the city’s growing affordable housing needs.  Working with Gardner Capital and their investment team at NDC, we have established a true public-private partnership.  Their projects are first class and more than meet the needs for the city and our citizens.  It has been a pleasure working with them, truly a partnership relationship, and much more than a traditional city and developer relationship.”

NDC Acquisition Manager, John Zaluski added “NDC is so excited to be a part of the Gala at Central Park project.  This project fits our mission to provide equity capital for the construction of affordable housing for low-income individuals across the country.”  Since its inception, NDC’s affordable housing group has raised over $1 billion of equity, which has resulted in over 15,000 units of housing created.

The 94-unit senior complex, with a mix of one- and two-bedroom apartments, will include a three-story residential building and a two-story clubhouse with a variety of resident amenities.

“As the need and demand for affordable senior housing continues to grow, we are thrilled to break ground and make a genuine difference in the market.  We are excited to continue to grow our long term commitment to investing in the City of Hurst as well as build upon our long term partnership with the City – a partnership that has and will continue to be a very important one, not only to our Company, but for me personally,” said Michael Gardner, President and CEO of Gardner Capital. Gala at Central Park is one of multiple transactions currently in development for Gardner Capital specific to the DFW Region, consisting of over 1,000 units to be completed in the next few years.

About Gardner Capital

Gardner Capital is a private equity firm with multiple operating businesses focused on affordable housing and renewable energy development, tax credit syndication, and real estate-related investments with offices in St. Louis, Dallas, Houston, and Orlando. Since 1992, Gardner Capital has placed more than $3 billion of equity in affordable housing and related investments. In recent years, Gardner Capital added a rapidly growing national platform for solar development and investment and expanded its commitment to renewable energy and sustainability across its investment platform and operating companies. Gardner Capital is committed to investing in communities, creating upward mobility, and improving the wellbeing of families by developing, investing and raising capital for affordable housing and clean energy-related businesses.

Continue Reading

News

Tejas Networks wins an international order of USD 13 Million from South-East Asia region

Published

on

Tejas Networks wins an international order of USD 13 Million from South-East Asia region

Tejas Networks (BSE: 540595) (NSE: TEJASNET) today announced that it has received a purchase order of $13 million from a leading telecommunications service provider in South East Asia. As per the contract, Tejas will supply and install its award-winning TJ1400 ultra-converged broadband products (TJ1400UCB) to extend high-speed broadband services to underserved rural communities in the region. The project is expected to be executed within the next 12 months.

Mr. Sanjay Nayak, Managing Director and CEO of Tejas Networks said, “We are delighted to be chosen for this prestigious project that will enable a sizable rural population to experience the tangible benefits of high-speed, reliable and affordable wireless internet for the first time. TJ1400UCB is an innovative product that provides the flexibility to rapidly rollout broadband services on optical fiber, wireless or copper media, as per available infrastructure, at highly affordable costs. Tejas was selected because of our cutting-edge products, as well as our vast experience in timely rollouts of large-scale broadband access and optical transmission networks around the globe, including Government of India’s BharatNet and Railway WiFi projects.”

Dr. Kumar N. Sivarajan, Chief Technology Officer (CTO) of Tejas Networks, said, “We are excited that Tejas has been selected as the primary telecom equipment supplier for this challenging project. Ubiquitous and affordable broadband has become a necessity in modern life and is a critical tool to deliver advanced services such as telemedicine, e-education, online banking, e-commerce and e-governance services. TJ1400UCB leverages our unique software-defined hardware™ architecture to seamlessly integrate state-of-the-art broadband access technologies and high-capacity packet transmission services in one shelf with the added benefits of unified management, space reduction and power savings to achieve a cost-effective rollout.”

About Tejas Networks Limited

Tejas Networks designs, develops and sells high-performance and cost-competitive networking products to telecommunications service providers, internet service providers, utilities, defence and government entities in over 75 countries. Tejas products utilize programmable, software-defined hardware architecture with a common software code-base that delivers seamless upgrades of new features and technology standards. Tejas Networks is ranked among top-10 suppliers in the global optical aggregation segment and has filed over 349 patents.

Continue Reading

Trending

Copyright © 2020. All Biz Post